166 related articles for article (PubMed ID: 31943585)
1. Potent Dual BET/HDAC Inhibitors for Efficient Treatment of Pancreatic Cancer.
He S; Dong G; Li Y; Wu S; Wang W; Sheng C
Angew Chem Int Ed Engl; 2020 Feb; 59(8):3028-3032. PubMed ID: 31943585
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
Zhang X; Zegar T; Weiser T; Hamdan FH; Berger BT; Lucas R; Balourdas DI; Ladigan S; Cheung PF; Liffers ST; Trajkovic-Arsic M; Scheffler B; Joerger AC; Hahn SA; Johnsen SA; Knapp S; Siveke JT
Int J Cancer; 2020 Nov; 147(10):2847-2861. PubMed ID: 32599645
[TBL] [Abstract][Full Text] [Related]
3. Development of Potent Dual BET/HDAC Inhibitors via Pharmacophore Merging and Structure-Guided Optimization.
Bauer N; Balourdas DI; Schneider JR; Zhang X; Berger LM; Berger BT; Schwalm MP; Klopp NA; Siveke JT; Knapp S; Joerger AC
ACS Chem Biol; 2024 Feb; 19(2):266-279. PubMed ID: 38291964
[TBL] [Abstract][Full Text] [Related]
4. BET-HDAC Dual Inhibitors for Combinational Treatment of Breast Cancer and Concurrent Candidiasis.
Huang Y; Liu N; Pan Z; Li Z; Sheng C
J Med Chem; 2023 Jan; 66(2):1239-1253. PubMed ID: 36622852
[TBL] [Abstract][Full Text] [Related]
5. The dual FAK-HDAC inhibitor MY-1259 displays potent activities in gastric cancers in vitro and in vivo.
Song J; Liu X; Zhang YF; Tian XY; Deng MY; Huang CZ; Zhang SY
Bioorg Chem; 2023 Feb; 131():106328. PubMed ID: 36542986
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis and in vitro antiproliferative effects studies of novel dual BRD4/HDAC inhibitors.
Shao M; He L; Zheng L; Huang L; Zhou Y; Wang T; Chen Y; Shen M; Wang F; Yang Z; Chen L
Bioorg Med Chem Lett; 2017 Sep; 27(17):4051-4055. PubMed ID: 28765013
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.
Dong G; Chen W; Wang X; Yang X; Xu T; Wang P; Zhang W; Rao Y; Miao C; Sheng C
J Med Chem; 2017 Oct; 60(19):7965-7983. PubMed ID: 28885834
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Src Homology-2 Domain-Containing Phosphatase 2 and Histone Deacetylase Dual Inhibitors with Potent Antitumor Efficacy and Enhanced Antitumor Immunity.
Liu M; Gao S; Liang T; Qiu X; Yang X; Fang H; Hou X
J Med Chem; 2022 Sep; 65(18):12200-12218. PubMed ID: 36097406
[TBL] [Abstract][Full Text] [Related]
10. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2.
Yu Y; Ran D; Jiang J; Pan T; Dan Y; Tang Q; Li W; Zhang L; Gan L; Gan Z
Bioorg Med Chem Lett; 2019 Aug; 29(16):2136-2140. PubMed ID: 31272794
[TBL] [Abstract][Full Text] [Related]
12. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
13. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
14. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel dual c-Met/HDAC inhibitors as a promising strategy for cancer therapy.
Hu H; Chen F; Dong Y; Liu Y; Gong P
Bioorg Chem; 2020 Aug; 101():103970. PubMed ID: 32480172
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors.
Geng A; Cui H; Zhang L; Chen X; Li H; Lu T; Zhu Y
Bioorg Med Chem Lett; 2019 Jul; 29(13):1605-1608. PubMed ID: 31053508
[TBL] [Abstract][Full Text] [Related]
17. Co-targeting of BET proteins and HDACs as a novel approach to trigger apoptosis in rhabdomyosarcoma cells.
Enßle JC; Boedicker C; Wanior M; Vogler M; Knapp S; Fulda S
Cancer Lett; 2018 Aug; 428():160-172. PubMed ID: 29709701
[TBL] [Abstract][Full Text] [Related]
18. Dual BET/HDAC inhibition to relieve neuropathic pain: Recent advances, perspectives, and future opportunities.
Romanelli MN; Borgonetti V; Galeotti N
Pharmacol Res; 2021 Nov; 173():105901. PubMed ID: 34547384
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Thieno[2,3-
Pan Z; Li X; Wang Y; Jiang Q; Jiang L; Zhang M; Zhang N; Wu F; Liu B; He G
J Med Chem; 2020 Apr; 63(7):3678-3700. PubMed ID: 32153186
[TBL] [Abstract][Full Text] [Related]
20. Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer.
Damaskos C; Garmpis N; Karatzas T; Nikolidakis L; Kostakis ID; Garmpi A; Karamaroudis S; Boutsikos G; Damaskou Z; Kostakis A; Kouraklis G
Anticancer Res; 2015 Jun; 35(6):3129-35. PubMed ID: 26026072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
